GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » Price-to-Owner-Earnings

Corestemchemon (XKRX:166480) Price-to-Owner-Earnings : (As of May. 31, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Corestemchemon Price-to-Owner-Earnings?

As of today (2025-05-31), Corestemchemon's share price is ₩3120.00. Corestemchemon does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Corestemchemon's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Corestemchemon was 22718.63. The lowest was 16749.05. And the median was 20532.32.


XKRX:166480's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.765
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-31), Corestemchemon's share price is ₩3120.00. Corestemchemon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-712.00. Therefore, Corestemchemon's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-31), Corestemchemon's share price is ₩3120.00. Corestemchemon's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-880.18. Therefore, Corestemchemon's PE Ratio without NRI for today is At Loss.


Corestemchemon Price-to-Owner-Earnings Historical Data

The historical data trend for Corestemchemon's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corestemchemon Price-to-Owner-Earnings Chart

Corestemchemon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corestemchemon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corestemchemon's Price-to-Owner-Earnings

For the Biotechnology subindustry, Corestemchemon's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corestemchemon's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corestemchemon's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Corestemchemon's Price-to-Owner-Earnings falls into.


;
;

Corestemchemon Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Corestemchemon's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3120.00/-1750.23
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corestemchemon  (XKRX:166480) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Corestemchemon Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Corestemchemon's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Corestemchemon Business Description

Traded in Other Exchanges
N/A
Address
Pangyo 255 beongil 24 I & C Building, 2nd Floor, yeonggi-do, Bundang-gu, Seongnam, Seoul, KOR, 13486
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

Corestemchemon Headlines

No Headlines